Use of Surrogate Markers and Algorithms to Identify High Risk Patien…

Scripps Health

N. Alkhouri

MAFLD: What Is It?

Houston Methodist

D. Victor

Best Practices In Managing NAFLD / NASH

MedNews Week

D. Bernstein

The Fatty Liver Disease Epidemic

UPMC

M. Klinge

Major Advancements in MASH Management

Rush University Medical Center

S. Janardhan

Using Resmetirom (THR-β Agonist) in Your Practice for MASH

Scripps Health

J. Gutierrez

New Therapy for Fatty Liver Disease

Washington University in St. Louis

K. Korenblat

Debate: Options for MASH Treatment, GLP-1 or Resmetirom?

Rush University Medical Center

S. Janardhan, N. Reau

MetALD: What Is It, and How Do We Manage It?

Rush University Medical Center

L. Ritchie

MASLD Updates Early 2025

Adrian Lindsey

Cutting Edge Diagnostics and Treatment for NAFLD

Northwestern Medicine Gastroenterology

M. E. Rinella, L. Van Wagner

Fatty Liver Disease: When to Refer?

Yale School of Medicine

NAFLD: Updates in Management

UChicago Medicine

M. E. Rinella

MASLD for the Non-Hepatologist: Insights from ADA Guidelines

Washington University in St. Louis

K. Williams

Caring for the Post Liver Transplant Patient in the Primary Care Set…

University of Colorado Department of Medicine

B. Henderson, M. O'Meara

Updates on Management of NASH

Pennsylvania Society of Gastroenterology

T. Singh

Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD/MASH…

Pennsylvania Society of Gastroenterology

M. Lagarde

Non-Alcoholic Fatty Liver Disease: Where Are We in 2023?

Houston Methodist

N. Gunn

End to End GI Pathology (and the Liver, Too!)

UCSF School of Medicine

J. (J. P.) Grenert

Heart and Liver Interactions

Houston Methodist DeBakey Heart and Vascular Center

S. Adeel Ahsan